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Background: Increased serum urate levels are associated with poor outcomes including but not limited to gout. It
is unclear whether serum urate levels are the sole predictor of incident hyperuricemia or whether demographic and
clinical risk factors also predict the development of hyperuricemia. The goal of this study was to identify risk factors
for incident hyperuricemia over 9 years in a population-based study, ARIC.
Methods: ARIC recruited individuals from 4 US communities; 8,342 participants who had urate levels <7.0 mg/dL
were included in this analysis. Risk factors (including baseline, 3-year, and change in urate level over 3 years) for
9-year incident hyperuricemia (urate level of >7.0 g/dL) were identified using an AIC-based selection approach in a
modified Poisson regression model.
Results: The 9-year cumulative incidence of hyperuricemia was 4%; men = 5%; women = 3%; African Americans = 6%
and whites = 3%. The adjusted model included 9 predictors for incident hyperuricemia over 9 years: male sex (RR = 1.73
95% CI: 1.36-2.21), African-American race (RR = 1.79 95% CI: 1.37-2.33), smoking (RR = 1.27, 95% CI: 0.97-1.67), <HS
education (RR = 1.27, 95% CI: 0.99-1.63), hypertension (RR = 1.65, 95% CI: 1.30-2.09), CHD (RR = 1.57, 95% CI: 0.99-2.50),
obesity (class I RR = 2.37, 95% CI: 1.65-3.41 and ≥ class II RR = 3.47, 95% CI: 2.33-5.18), eGFR < 60 (RR = 2.85, 95% CI:
1.62-5.01) and triglycerides (Quartile 4 vs. Quartile 1: RR = 2.00, 95% CI: 1.38-2.89). In separate models, urate levels at
baseline (RR 1 mg/dL increase = 2.33, 95% CI: 1.94-2.80) and 3 years after baseline (RR for a 1 mg/dL increase = 1.92, 95%
CI: 1.78-2.07) were associated with incident hyperuricemia after accounting for demographic and clinical risk factors.
Conclusion: Demographic and clinical risk factors that are routinely collected as part of regular medical care are jointly
associated with the development of hyperuricemia.
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Increased serum urate levels are associated with poor
outcomes including but not limited to gout [1-11]. There
are clear differences in serum urate levels by age, sex,
and race. Young adult women are known to have lower
serum urate levels than young adult men, [12] which is
primarily attributable to sex hormone effects on renal
urate transport [13]. The onset of menopause is associated
with increased serum urate levels [13,14]. Additionally,* Correspondence: mmcadams@jhsph.edu
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distribution, and reproduction in any mediumyoung African Americans have lower serum urate levels
than whites; although African American women are at
a higher risk than white women of developing hyperuri-
cemia [12]. Previous studies have identified individual
risk factors for increased serum urate levels and incident
hyperuricemia in US populations in addition to age, sex,
and race: diet, alcohol intake, medication use, and chronic
conditions [12,13,15-22].
In current clinical practice, patients with asymptom-
atic hyperuricemia are not treated. Emerging research
suggests that treatment of asymptomatic hyperuricemia
may reduce the risk of some adverse health outcomes,
such as mortality and cardiovascular disease; [23-27]
therefore, treatment of asymptomatic hyperuricemia isMed Central Ltd. This is an open access article distributed under the terms of
tp://creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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comes [28,29]. Better understanding of which patients are
at risk of developing hyperuricemia may aid in clinical
decision-making about treatment of asymptomatic hyper-
uricemia. However, hyperuricemia risk prediction has
been limited because previously published studies were
cross-sectional, [12,14,17,21,22] and thus, only correlates
of prevalent serum urate were identified in these studies.
These cross-sectional studies do not distinguish whether
the clinical factors associated with serum urate level
predated the onset of hyperuricemia or whether hyperuri-
cemia led to the onset of these clinical factors. Prospective
studies of both men and women without hyperuricemia
that follow participants until they develop this outcome
are needed for accurate risk prediction to inform clinical
decision-making. Additionally, these previous studies
focused only on a single correlate of serum urate level
[14,19-21]. However, optimum risk prediction for hy-
peruricemia requires the simultaneous assessment of
the risk inferred by a combination of risk factors.
It is unclear what demographic and clinical risk factors
contribute to the development of high uric acid levels
and whether serum urate levels are the sole predictor
of incident hyperuricemia or whether demographic
and clinical risk factors also predict the development
of hyperuricemia (>7.0 mg/dL). Therefore, we utilized a
population-based cohort study that included prospective
measurement of a range of demographic and clinical risk
factors among African American and white, middle-aged
men and women to identify risk factors for the develop-
ment of hyperuricemia over 9 years.
Methods
Setting and participants
The Atherosclerosis Risk in Communities study (ARIC)
is a prospective population-based cohort study of
15,792 individuals recruited from 4 US communities
(Washington County, Maryland; Forsyth County, North
Carolina; Jackson, Mississippi; and suburbs of Minneapolis,
Minnesota). The Institutional Review Board of the partici-
pating institutions (Johns Hopkins University, University
of North Carolina at Chapel Hill, Wake Forest Baptist
Medical Center, University of Mississippi Medical Center,
and University of Minnesota) approved the ARIC study
protocol and study participants provided written informed
consent. Participants aged 45 to 64 years were recruited
to the cohort in 1987–1989. This cohort was established
to study the natural history of atherosclerosis, and the
study consisted of 1 baseline visit (visit 1) between 1987
and 1989 and 3 follow-up visits (visits 2, 3, and 4) admin-
istered 3 years apart. Details of the study design have
been previously published [30].
We excluded participants with prevalent hyperurice-
mia at cohort entry, defined as a measured serum uratelevel >7.0 mg/dL at the baseline visit (n = 2,455) to ensure
that those study participants who were included in the
analysis were at risk of developing hyperuricemia during
follow-up. We additionally excluded those who were
missing baseline serum urate level (n = 77) because we
were unsure whether or not they had hyperuricemia at
baseline. This analysis was limited to participants who
were Caucasian or African American; few participants
reported other races (n = 48). Additionally, participants
who did not have a subsequent urate measure were not
included in this study (n = 4,288). Results were similar
when multiple imputation was used to include participants
with missing serum or plasma urate levels. Finally, we
only included participants with complete ascertainment
of demographic and clinical risk factors (n = 582 excluded).
There were 8,342 participants included in our study;
however, 8,211 participants were included in the analyses
that adjusted for serum urate level at visit 2 due to the fact
that 131 participants in the analytic cohort did not have
a measure of serum urate level at visit 2. Participants
who were excluded from this analysis did not differ on
sex or age. However, they were more likely to be African-
American (37% vs. 19%). Additionally, participants with
missing plasma urate at visit 4 differed from those with
available plasma urate based on baseline smoking status
(39% vs. 23%), hypertension (38% vs. 26%), diabetes (17%
vs. 8%), CHD (7% vs. 3%), and obesity (27% vs. 22%).
Hyperuricemia
Serum urate concentrations were measured with the
uricase method at visit 1 and 2 in mg/dL [31]. The reliabil-
ity coefficient of serum urate was 0.91, and the coefficient
of variation was 7.2% in a sample of 40 individuals with
repeated measures taken at least 1 week apart [32]. At visit
4 plasma urate level was measured in mg/dL and hyper-
uricemia was defined as a plasma urate level >7.0 mg/dL
at this visit. Participants who were free of hyperuricemia
at visit 1 (by study design) and who had hyperuricemia
at visit 4 were considered to have 9-year incident
hyperuricemia.
Demographic and clinical risk factors
All demographic and clinical risk factors were assessed
at baseline and included: sex, age (in years), race (white
or African American), smoking status, education (less
than high school or high school and higher), diabetes,
hypertension (>140/90 mm Hg or use of an anti-hyper-
tensive treatment), diuretic use, coronary heart disease
(CHD), total/HDL cholesterol, triglycerides level (mg/dL,
categorized as quartiles), congestive heart failure (use
of a medication for heart failure or fulfillment of the
Gothenburg Criteria), body mass index (BMI, kg/m2),
early adult obesity (from self-reported weight at age
25), weight change from age 25 to baseline, waist-to-
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fat intake (grams/day), and menopausal status (self-re-
ported for women pre- and peri- vs. post-menopausal).
Glomerular filtration rate (eGFR) was estimated by using
the CKD-Epi equation [33] and categorized as ≥90, 60–90,
or <60 ml/min/1.73 m2. Categories were chosen to reduce
residual confounding. All risk factors were categorized
based on empirical categorizations to reflect the distri-
bution in the cohort.
Additionally, serum urate levels at visits 1 and 2 were
considered predictors of the future development of hy-
peruricemia. Baseline serum urate level, follow-up serum
urate level (measured 3-years after baseline), and 3-year
change in serum urate level were considered predictors
of hyperuricemia.
Analysis
First, the mean and standard deviation (SD) as well as
the prevalence of the covariates were calculated and
compared by incident hyperuricemia. The mean of con-
tinuous variables in those with incident hyperuricemia
was compared with the mean of those who did not
develop hyperuricemia using a t-test; the prevalence of
categorical factors was compared using the Fisher’s
exact tests. For categorical factors with more than 2
levels, a test for trend was conducted using a nominal
value for each category.
Using modified Poisson regression, [34] the relative risk
(RR) of 9-year incident hyperuricemia was calculated.
All potential demographic and clinical risk factors, except
serum urate measures, were considered in the initial
model. We used an Akaike’s Information Criterion (AIC)-
based selection criteria to create a final model of pre-
dictors of 9-year incident hyperuricemia. Then, baseline
serum urate level, 3-year serum urate level, and 3-year
change in serum urate level were included as a predictor
of incident hyperuricemia in separate models that were
adjusted for demographic and clinical risk factors. In
sensitivity analysis, the threshold for serum urate level
was set at 6.8 mg/dL.
Results
Study cohort characteristics
There were 8,342 participants included in our study;
63% were female and 19% were African-American. The
9-year cumulative incidence of hyperuricemia was 4%
and subgroup cumulative incidence rates were: 5% for
men; 3% for women; 6% for African Americans and 3%
for whites.
Cohort demographic and clinical risk factors differed
by incident hyperuricemia status (Table 1). Overall, par-
ticipants who developed hyperuricemia were more likely
to be male (49% vs. 37%, p-value < 0.001), and African
American (33% vs. 18%, p-value < 0.001), and were lesslikely to have a high school education or higher (73% vs.
83%, p-value < 0.001). Furthermore, participants who
developed hyperuricemia were more likely to have
chronic conditions at baseline: hypertension (44% vs.
24%, p-value < 0.001), obesity (BMI ≥ 30 kg/m2; 37% vs.
21%, p-value < 0.001), diabetes (11% vs. 8%, p-value < 0.05),
and CHD (6% vs. 3%, p-value < 0.05). Participants with
incident hyperuricemia were more likely to have an
eGFR <60 ml/min/1.73 m2 (4% vs. 1%) or 60–90 ml/
min/1.73 m2 (40% vs. 39%; p-value for trend < 0.001)
than those without hyperuricemia. Among female partici-
pants, who were free of hyperuricemia by design, there
was no difference in menopausal status at baseline and in-
cidence of hyperuricemia, which may be the result of the
exclusion of those with hyperuricemia at baseline
(Table 1).
Participants who developed hyperuricemia were more
likely to have a higher serum urate at baseline, even though
the level did not cross the threshold of hyperuricemia
by design (6.1 vs. 5.3 mg/dL, p-value < 0.001). This trend
persisted during follow-up (3 years after baseline) (7.0
vs. 5.5 mg/dL, p-value < 0.001). Furthermore, there was
a greater change in serum urate levels over 3 years
(0.87 vs. 0.19, p-value < 0.001) for those who developed
hyperuricemia.
Demographic and clinical risk factors for incident
hyperuricemia
The final adjusted model included 9 demographic and
clinical risk factors for incident hyperuricemia over
9 years (Table 2). Men were at 1.73-fold (95% CI: 1.36-
2.21) increased risk of developing hyperuricemia and
African-American participants were at 1.79-fold (95%
CI: 1.37-2.33) increased risk. Additional participant
demographics such as current smoker (RR = 1.27, 95%
CI: 0.97-1.67) and less than a high school education
(RR = 1.27, 95% CI: 0.99-1.63) were associated with an
increased risk of developing hyperuricemia. Participants
with hypertension were at 1.65-fold (95% CI: 1.30-2.09)
increased risk of developing hyperuricemia and CHD was
associated with an increased but not significant risk of
hyperuricemia (RR = 1.57, 95% CI: 0.99-2.50). Additionally,
BMI was a strong predictor of incident hyperuricemia;
there was an increased risk of developing hyperuricemia for
participants who were overweight (RR = 2.01, 95% CI: 1.46-
2.78), or had 30 ≤ BMI < 35 kg/m2 (RR = 2.37, 95% CI:
1.65-3.41) and BMI ≥ 35 kg/m2 (RR = 3.47, 95% CI: 2.33-
5.18). eGFR < 60 (RR = 2.85, 95% CI: 1.62-5.01) at base-
line was associated with incident hyperuricemia. Finally,
high triglyceride levels were a predictor of incident hyper-
uricemia (quartile 4 vs. quartile 1: RR = 2.00, 95% CI: 1.38-
2.89). There were no differences in the association of
smoking status, education, hypertension, BMI, or kidney
function between men and women as well as between






Baseline risk factors n = 7,908 n = 304
Male sex 37 49**
Age, years 53.8 (6) 54.3 (5)
African American race 18 33**
High school education or higher 83 73**
Pre-menopausea,b 35 37
Smoking statusa
Current smoker 22 27
Former smoker 31 28
Never smoker 47 45
Diuretic use 12 19**
Hypertension 24 44**
Total cholesterol, mmol/L 6 (1) 6 (1)
HDL cholesterola
< 1.03 mmol/L 20 26*
1.03 ≤ HDL ≤ 1.55 48 50
> 1.55 32 24
Diabetes 8 11*
Coronary heart disease 3 6*
Congestive heart failure 2 5*
BMI, kg/m2a
BMI ≥ 35 6 14**
30 ≤ BMI < 35 15 23
25 ≤ BMI < 30 39 45
BMI < 25 40 18
Early adult obesity 3 7**
Weight change from early adult, lb 25 (26) 32 (30)**
Waist-to-hip ratio, quartilesa
Waist-to-hip ratio ≥ 0.97 23 38**
0.92 ≤ Waist-to-hip ratio < 0.97 25 28
0.86 ≤Waist -to-hip ratio < 0.92 26 22






Animal fat, grams/day 35 (17) 37 (18)*




≥ 90 60 56
Table 1 Baseline risk factors by incident hyperuricemia in
the ARIC cohort (Continued)
Baseline serum urate
level, mg/dL
5.3 (1.0) 6.1 (0.78)**
Serum urate level at
3 year follow-up, mg/dL
5.5 (1.2) 7.0 (1.3)**
3-year change in serum
urate level, mg/dL
0.2 (0.9) 0.9 (1.3)**
Mean and standard deviation (SD) for continuous variables and percent for
categorical variables.
*p-value < 0.05 ; **p-value < 0.001.
ap-value for trend.
bThe number of participants included in analysis was 4,551; men (n = 3,036)
and women without known menopause status (n = 625) were excluded from
this analysis.
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for these interactions >0.05).Serum urate level and incident hyperuricemia
Serum urate levels at baseline (RR for a 1 mg/dL in-
crease =2.33, 95% CI: 1.94-2.80) and at visit 2 (RR for a
1 mg/dL increase =1.92, 95% CI: 1.78-2.07) were associated
with the development of hyperuricemia after accounting
for demographic and clinical risk factors (Table 2). Adjust-
ing for baseline and follow-up (3 years after baseline) serum
urate levels attenuated the associations of the demo-
graphic and clinical risk factors for hyperuricemia.
Additionally, the 3-year change in serum urate level
was associated with an increased risk of hyperuricemia,
such that for every 1 mg/dL increase in serum urate,
participants were 1.60-times (95% CI: 1.47-1.74) more
likely to develop hyperuricemia after accounting for
demographic and clinical risk factors. The association of
serum urate level did not differ by sex (women RR = 2.49,
95% CI: 1.96-3.17; men RR = 2.41, 95% CI: 1.77-3.27;
p-value for interaction = 0.98).
The results did not materially change when we defined
incident hyperuricemia as a serum urate level >6.8 mg/dL.
Additionally, the results were similar when the analysis
was restricted to post-menopausal women (urate level
at visit 1: RR = 2.36, 95% CI: 1.65-3.37; urate level at
visit 2: RR = 1.96, 95% CI: 1.74-2.20; change in urate
level RR = 1.73, 95% CI: 1.50-2.01).Discussion
The results from this large population-based cohort of
middle-aged, African American and White, men and
women followed over 9 years help define significant
predictors of the onset of hyperuricemia. Although
baseline serum urate level was a strong predictor of the
incidence of hyperuricemia, it was not the sole factor.
Other risk factors, including sex, race and chronic








RR (95% CI)Risk factor
Male sex 1.73 (1.36, 2.21) 1.10 (0.85, 1.43) 1.02 (0.80, 1.31) 1.54 (1.21, 1.97)
African American race 1.79 (1.37, 2.33) 1.68 (1.29, 2.18) 1.50 (1.15, 1.94) 1.64 (1.26, 2.13)
<High school education 1.27 (0.99, 1.63) 1.29 (1.00, 1.65) 1.15 (0.89, 1.49) 1.23 (0.96, 1.58)
Hypertension 1.65 (1.3, 2.09) 1.47 (1.15, 1.87) 1.27 (0.99, 1.62) 1.44 (1.12, 1.84)
Coronary heart disease 1.57 (0.99, 2.50) 1.60 (1.00, 2.56) 1.48 (0.90, 2.43) 1.45 (0.89, 2.37)
Smoking status
Current smoker 1.27 (0.97, 1.67) 1.29 (0.98, 1.69) 1.26 (0.96, 1.66) 1.27 (0.96, 1.66)
Former smoker 0.84 (0.64, 1.11) 0.81 (0.62, 1.07) 0.78 (0.60, 1.03) 0.83 (0.63, 1.09)
Never smoker Reference Reference Reference Reference
Body mass index, kg/m2
BMI ≥ 35 3.47 (2.33, 5.18) 2.07 (1.37, 3.14) 2.18 (1.44, 3.31) 3.25 (2.16, 4.9)
30 ≤ BMI < 35 2.37 (1.65, 3.41) 1.76 (1.22, 2.54) 1.90 (1.31, 2.75) 2.37 (1.64, 3.40)
25 ≤ BMI < 30 2.01 (1.46, 2.78) 1.64 (1.19, 2.26) 1.79 (1.30, 2.46) 2.04 (1.48, 2.81)
BMI < 25 Reference Reference Reference Reference
eGFR, ml/min/1.73 m2
<60 2.85 (1.62, 5.01) 1.97 (1.12, 3.47) 2.05 (1.24, 3.39) 2.86 (1.70, 4.82)
60-90 1.12 (0.89, 1.42) 0.95 (0.75, 1.20) 1.05 (0.84, 1.32) 1.18 (0.94, 1.48)
≥ 90 Reference Reference Reference Reference
Triglyceride, mg/dL
Quartile 4: ≥ 157 2.00 (1.38, 2.89) 1.48 (1.03, 2.13) 1.44 (1.01, 2.04) 1.93 (1.35, 2.76)
Quartile 3: 110 -156 1.46 (1.01, 2.12) 1.20 (0.83, 1.73) 1.12 (0.79, 1.60) 1.41 (0.99, 2.02)
Quartile 2: 79 - 109 1.08 (0.73, 1.60) 0.96 (0.65, 1.41) 1.00 (0.68, 1.46) 1.12 (0.76, 1.65)
Quartile 1: ≤ 78 Reference Reference Reference Reference
Serum Urate Level at Visit1, mg/dL 2.33 (1.94, 2.80)
Serum Urate Level at Visit2, mg/dL 1.92 (1.78, 2.07)
Change in serum urate level (Visit 2-Visit 1), mg/dL 1.60 (1.47, 1.74)
aThe number of participants included in analysis was 8,342.
bThe number of participants included in analysis was 8,211.
Note: Relative risks and 95% confidence intervals are reported. Each model includes all the risk factors with relative risks and 95% confidence intervals listed in
the column. Hyperuricemia was defined as serum urate levels greater than 7.0 mg/dL.
McAdams-DeMarco et al. BMC Musculoskeletal Disorders 2013, 14:347 Page 5 of 8
http://www.biomedcentral.com/1471-2474/14/347conditions, were important predictors of incident hy-
peruricemia above and beyond serum urate levels.
Our findings support and extend previous observations
concerning risk factors for gout and hyperuricemia. Simi-
lar to prior studies, we determined that African Americans
have an increased risk of incident hyperuricemia relative
to whites. The effect was similar for African American
men and women [35]. Congestive heart failure (RR = 1.67,
95% CI: 1.21-2.23) and diuretic use (RR = 3.32, 95% CI:
3.06-3.61) were associated with hyperuricemia among men
with a high cardiovascular risk profile in the Multiple
Risk Factor Interventional Trial [19]. However, the ARIC
cohort is a low cardiovascular disease risk population and
we did not identify these factors as predictors of incident
hyperuricemia. Our study supports previous ones that
identified modifiable risk factors as correlates of serumurate level [15,17,36]. In our study, BMI was a strong
predictor, although alcohol intake was not independently
associated with incident hyperuricemia. In contrast to
previous cross sectional studies, [16] our multivariate
analyses did not support an association of dietary factors
with incident hyperuricemia in this cohort. One possible
explanation for why the dietary factors were not associated
with incident hyperuricemia is that by middle age, chronic
conditions like obesity, hypertension, and kidney disease,
are more likely to influence the development of hyper-
uricemia than the transient effects of dietary changes.
Additionally, our measure of usual dietary intake may
not fully capture the variation in purine-rich foods and
thus, including these dietary factors may not improve
our ability to predict who develops hyperuricemia. Finally,
among women, we did not observe an association between
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been noted in other studies [13]. This finding may reflect
the fact that our study population was middle-aged at
enrollment and few female participants were pre-meno-
pausal at the time of outcome ascertainment.
In current clinical practice, patients with asymptomatic
hyperuricemia are not treated. This practice was strongly
recommended in 1978 based on limited evidence at the
time that hyperuricemia was associated with hypertension,
atherosclerosis, cerebrovascular disease, as well as renal
stones, and gouty nephropathy [37]. However, since 1978,
many research studies have focused on the consequences
of hyperuricemia providing strong evidence that links
hyperuricemia directly to not only gout but other poor
outcomes such as heart failure, atherosclerosis, endo-
thelial dysfunction, sleep disordered breathing, diabetic
nephropathy, metabolic syndrome, acute myocardial in-
farction, stroke, ischemic heart disease, hypertension,
chronic kidney disease, acute kidney injury, and death
[3-11,23,38-50]. Additionally, there is growing evidence
that treatment of asymptomatic hyperuricemia improves
health outcomes for patients. Treatment of asymptomatic
hyperuricemia is currently being discussed to prevent
adverse health outcomes [28,29].
Treatment of asymptomatic hyperuricemia has been
found to improve health outcomes in patients. There is
emerging evidence that reductions in serum urate levels
have led to improved health including improvements in
endothelial dysfunction, inflammation, and kidney function
in asymptomatic patients [23-26] and cardiovascular events
and mortality among those with prescribed allopurinol
[27]. Evidence from clinical trials suggests that treatment
of asymptomatic hyperuricemia controls essential hyper-
tension [51]. In obese adolescents with prehypertension,
urate lowering therapy reduced systolic BP by 10.2 mm
Hg and diastolic BP by 9.0 mm Hg in treated patients
compared with a rise of 1.7 mm Hg and 1.6 mm Hg in
systolic and diastolic blood pressure for patients on
placebo [52]. Therefore, urate lowering therapy reduces
systemic vascular resistance [52]. Our findings may help
guide clinical decision-making to help identify which
patients are at highest risk of developing hyperuricemia
based on patient characteristics, chronic conditions, and
serum urate levels.
There are a few notable limitations to this study. First,
we do not have measures of serum urate level prior to
enrollment in ARIC. Therefore, we cannot be certain that
incident hyperuricemia over follow-up is truly the first
occurrence of hyperuricemia. Next, not all participants
had a measure of serum urate level after baseline. There
is limited evidence of differential missing plasma urate
measures and thus, the potential for survival bias is
minimal. There was no serum measure of sex hormones,
which have been associated with serum urate level [53].Therefore we were unable to assess the impact of sex
hormones on the incidence of hyperuricemia. Further-
more, there were too few pre- or peri-menopausal women
with hyperuricemia (n = 51) to identify risk factors in this
subgroup. Additionally, there were no participants who
had received kidney transplantation, a strong risk factor
for hyperuricemia, and thus our results are not general-
izable to this clinical population [54]. The strengths of this
study include multiple measures of serum urate, which
allows for the analysis of incident hyperuricemia rather
than correlates of serum urate level. Furthermore, ARIC is
a rich cohort with detailed data collection from African
American and white, men and women.Conclusions
These study findings extend the previous research of
correlates to serum urate level to the development of
incident hyperuricemia. Our results suggest that serum
urate levels alone do not predict incident hyperuricemia;
patient characteristics and chronic conditions are also
predictors of the development of hyperuricemia. The
factors identified as predictors of incident hyperuricemia
are routinely collected as part of regular medical and may
be readily incorporated into risk prediction. Future work
should establish the clinical effectiveness of predicting and
treating incident hyperuricemia to prevent the onset of
gout and other adverse outcomes.Competing interest
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